Oreos maker Mondelez International recently said it expected a drop in profit due to rising cocoa prices, which have prompted ...

For any one with a straining waistband, the next step was once a given: heading to the local church hall for an evening of ...

But this is just the start. GLP-1 drugs (specifically Novo Nordisk’s Ozempic, Rybelsus and Wegovy and Eli Lilly’s Mounjaro ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

Wegovy and Zepbound are just the latest drug dyads to face-off in the competitive pharma market, continuing a legacy of ...

Study results in a rare form of obesity could help the company expand use of Imcivree, which is approved for two genetically ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

The Trump administration rejected a proposed rule to allow Medicare to cover blockbuster obesity drugs for weight loss alone ...

"First, I eat far less. That seems to be what everyone on Wegovy does. Second, I eat totally different things vs before," ...

The decision is a setback for GLP-1 drugmakers, though it's not entirely surprising given the Trump administration’s focus on ...

States increasingly struggling to cover the rising cost of popular GLP-1 drugs like Wegovy, Ozempic and Zepbound are ...

President Donald Trump’s administration has decided not to cover expensive, high-demand obesity treatments under the federal ...